Gain Therapeutics Inc
GANX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$48.2M
Close$
$0.61
45.1% downside
Current Fair Value
45.1% downsideOvervalued by 45.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $48.20 Million |
|---|---|
| Enterprise Value | $35.71 Million |
| Earnings per Share | $-0.61 |
| Beta | 0.19 |
| Outstanding Shares | 42,879,541 |
Return
| Return on Equity | -178.06% |
|---|---|
| Return on Assets | -130.37% |
| Return on Invested Capital | -159.54% |
Valuation & Multiples
| P/E Ratio | -2.26 |
|---|---|
| PEG | 11.58 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.87 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.14
Consensus analyst estimateRevenue Estimate
$33,333
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.13
Consensus analyst estimateRevenue Estimate
$33,333
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 32.10% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.15%▼ 20.05% |
|---|---|
| Total Invested | $111,385▼ 99.36% |
| Investors Holding | 4▼ 50.00% |
About Gain Therapeutics Inc
16 employees
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options fo...